Latest Forum Topics /
IX Biopharma
Last:0.34
-0.015
|
 Post Reply
|
|
iX Biopharma
|
|||||
|
SmallSmall
Supreme |
05-Nov-2025 13:01
|
||||
|
x 0
x 0 Alert Admin |
Should move towards $0.15 first before going for the $0.20 level. This is a stock you should not short. Be patient
|
||||
| Useful To Me Not Useful To Me | |||||
|
easywin
Supreme |
05-Nov-2025 12:55
|
||||
|
x 0
x 0 Alert Admin |
Now many retails buy also scared sold too early regret. how?? | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
SmallSmall
Supreme |
05-Nov-2025 11:49
|
||||
|
x 0
x 0 Alert Admin |
Hovering at 52 week high now despite placements @ $0.10. Someone is mopping up the shares for sure.... Looks like another Sanli in the making |
||||
| Useful To Me Not Useful To Me | |||||
|
tofudidi
Supreme |
05-Nov-2025 09:32
|
||||
|
x 0
x 0 Alert Admin |
Wonder which big hand keep supporting? seems like some news is brewing | ||||
| Useful To Me Not Useful To Me | |||||
|
tofudidi
Supreme |
05-Nov-2025 09:28
|
||||
|
x 0
x 0 Alert Admin |
catch shortist ah!! breakout 140 ! 
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
tofudidi
Supreme |
05-Nov-2025 09:25
|
||||
|
x 0
x 0 Alert Admin |
salted fish turning alive! wait for the breakout 140 first...
|
||||
| Useful To Me Not Useful To Me | |||||
|
piscesmonkey
Supreme |
05-Nov-2025 09:22
|
||||
|
x 0
x 1 Alert Admin |
Bought at 128 200lots lot very strong today | ||||
| Useful To Me Not Useful To Me | |||||
|
ahberngh
Elite |
05-Nov-2025 09:21
|
||||
|
x 0
x 0 Alert Admin |
I sense that this stock is waiting to explode. Any good news and it will shoot up. Wait and see, fingers crossed. Please dyodd.
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
treetops
Elite |
05-Nov-2025 09:21
Yells: "Moments Today, Memories Tomorrow!" |
||||
|
x 0
x 0 Alert Admin |
When market is bad, penny stocks rise... | ||||
| Useful To Me Not Useful To Me | |||||
|
tofudidi
Supreme |
05-Nov-2025 09:20
|
||||
|
x 0
x 0 Alert Admin |
good breakout.. likely heading 150 range | ||||
| Useful To Me Not Useful To Me | |||||
|
SmallSmall
Supreme |
05-Nov-2025 09:18
|
||||
|
x 0
x 0 Alert Admin |
This stock cannot short....Lion and AGT inside | ||||
| Useful To Me Not Useful To Me | |||||
|
piscesmonkey
Supreme |
04-Nov-2025 12:53
|
||||
|
x 0
x 1 Alert Admin |
I means livingstone 😂
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
easywin
Supreme |
04-Nov-2025 12:14
|
||||
|
x 0
x 0 Alert Admin |
Above 130 after iunch?
|
||||
| Useful To Me Not Useful To Me | |||||
|
piscesmonkey
Supreme |
04-Nov-2025 11:57
|
||||
|
x 0
x 1 Alert Admin |
Soon annouce Profit Guidance for good result.
|
||||
| Useful To Me Not Useful To Me | |||||
|
longterminvestor
Master |
04-Nov-2025 09:27
|
||||
|
x 0
x 0 Alert Admin |
Livingstone health can see | ||||
| Useful To Me Not Useful To Me | |||||
|
piscesmonkey
Supreme |
04-Nov-2025 09:08
|
||||
|
x 0
x 1 Alert Admin |
I sold off at 126 200lots bought 113/114 small small play
|
||||
| Useful To Me Not Useful To Me | |||||
|
SmallSmall
Supreme |
31-Oct-2025 20:09
|
||||
|
x 0
x 0 Alert Admin |
NEWS RELEASE iX Biopharma Raises S$6.7 Million to Accelerate U.S. Expansion ü 34% higher than the initial S$5.0m target, following strong demand ü Institutional participation from Lion Global Investors Limited (a member of the OCBC Group) and Ginko-AGT Global Growth Fund SINGAPORE, 31 October 2025 &mdash iX Biopharma Ltd. (SGX: 42C) (&ldquo iX Biopharma&rdquo or &ldquo the Company&rdquo ) has completed its upsized share placement, raising S$6.7 million after demand exceeded the original S$5.0 million target. The Company issued 67,000,000 new shares at S$0.10 each. Investors include prominent funds like Lion Global Investors Limited (as investment manager for clients) and Ginko-AGT Global Growth Fund. OCBC Bank acted as Placement Agent. Eva Tan, Chief Commercial Officer of the Company, said: &ldquo The placement demand is a strong endorsement of our strategy to expand into the U.S. through compounding pharmacies, a model that allows immediate commercialisation of our novel sublingual products without further R& D investment. It reflects investors&rsquo confidence in our turnaround and gives us the resources to scale.&rdquo The entry into the U.S. market gives iX Biopharma access to the world&rsquo s largest healthcare market. The Company will focus on its compounding and wellness businesses, anchored by its market-leading SL-NAD+ and other products that support longevity and healthspan. Alongside its drug development division, these three pillars form the foundation for iX Biopharma&rsquo s next phase of growth. This media release should be read together with the Company&rsquo s SGXNET announcements dated 28 October 2025, 30 October 2025 and 31 October 2025 relating to the Placement. |
||||
| Useful To Me Not Useful To Me | |||||
|
Stocky901
Supreme |
30-Oct-2025 09:37
|
||||
|
x 0
x 0 Alert Admin |
Waiting for big junks of contra due throwing to you? Smart 👍
|
||||
| Useful To Me Not Useful To Me | |||||
|
labuubuuu
Veteran |
30-Oct-2025 09:34
|
||||
|
x 0
x 0 Alert Admin |
Patience wait for due day of contra | ||||
| Useful To Me Not Useful To Me | |||||
|
Joelton
Supreme |
30-Oct-2025 09:04
|
||||
|
x 0
x 0 Alert Admin |
iX Biopharma raises gross proceeds of S$6.7 million from placement
The amount surpasses the goal of S$5 million new shares issued at S$0.10 apiece
[SINGAPORE] Singapore-based speciality pharmaceutical and nutraceutical company iX Biopharma raised gross proceeds of S$6.7 million in a placement to raise funds for its expansion into the US.
The group had intended to raise at least S$5 million from the exercise, with new shares issued at S$0.10 apiece.
The number of new shares to be issued was increased due to strong investor demand, the company said on Tuesday (Oct 28).
Investors who subscribed for the new shares include Lion Global Investors and Ginko-AGT Global Growth Fund.
The 67 million new shares represent approximately 7.5 per cent of the existing issued and paid-up share capital of the company, consisting of 888.8 million shares.
iX Biopharma will use S$2 million of the proceeds to finance expenses linked to its expansion into the US, S$1.5 million to purchase equipment, S$1.8 million for general working capital as well as fees and expenses incurred in connection with the placement, and S$1.4 million to repay debts.
|
||||
| Useful To Me Not Useful To Me | |||||